Validation of a novel biomarker classifier that predicts radiation response following breast-conserving surgery for ductal carcinoma in situ (DCIS)

验证一种新型生物标志物分类器，可预测导管原位癌 (DCIS) 保乳手术后的放射反应

• 批准号: 470541
• 负责人: Rakovitch Eileen
• 金额: $ 144.34万
• 依托单位: Sunnybrook Research Institute (Toronto, Ontario)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-09-01 至 2026-09-01
• 项目状态: 未结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=470541&lang=en
• 关键词: Biomarkers; Breast Cancer; Dcis; Ductal Carcinoma In Situ; Progression; Radiotherapy; Recurrence

Ductal carcinoma in situ (DCIS) is a non-invasive type of breast cancer. Treatment of DCIS is recommended as some DCIS tumors can develop into invasive breast cancer. Most women are treated with breast-conserving surgery followed by breast radiation (RT)

导管原位癌（DCIS）是一种非侵袭性乳腺癌。建议治疗导管原位癌，因为一些导管原位癌肿瘤可能发展成浸润性乳腺癌。大多数女性接受保乳手术，然后进行乳房放射 (RT)